A Phase I Open Label Multi Center Dose Escalation Study to Assess Safety Tolerability and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose Gemcitabine in Patients With Advanced Solid Malignancies.

Trial Profile

A Phase I Open Label Multi Center Dose Escalation Study to Assess Safety Tolerability and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose Gemcitabine in Patients With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2014

At a glance

  • Drugs AZD 7762 (Primary) ; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 03 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 May 2009 Planned end date changed from Jul 2009 to Jun 2011 as reported by ClinicalTrials.gov.
    • 16 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top